Unlocking Novel Cancer Therapies through Targeting of the PI3K Pathway
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (5 April 2024) | Viewed by 219
Special Issue Editor
Interests: phosphoinositides; leukocytes; signalling; inflammation; cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The PI3K pathway is aberrantly activated in numerous cancers at a high frequency. As such, durable and efficacious inhibition of this pathway in patients has been a major focus in developing cancer therapies. However, PI3K monotherapy often results in limited success and recurrence is common. There are also many clinical challenges associated with the currently approved PI3K inhibitors, including those associated with efficacy , safety, hepatoxicity, colitis, infection and hyperglycaemia, among others. As such, scientists have heavily invested in next-generation PI3K inhibitors as well as defining downstream nodes of PI3K signaling that address these short-comings, with the ultimate goal of identifying novel, precision therapeutic targets in cancer. This Special Issue of Cancers aims to highlight the development of next-generation PI3K-enzyme inhibitors and targeting downstream components of the PI3K-dependent pathway with a view to develop therapeutics with higher selectivity and efficacy and limited toxicities which are more tolerable for combination therapies. It will also consider new diagnostic approaches to identify patients who are most likely to respond and benefit from both existing and new therapies.
Prof. Dr. Stephen Ward
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PI3K
- AKT
- mTOR
- inhibitors
- biomarkers
- immunology
- epigenomics
- precision
- immuno-oncology
- phosphatases
